Home Ultra-sensitive troponin I levels to exclude acute myocardial infarction from myocardial injury
Article
Licensed
Unlicensed Requires Authentication

Ultra-sensitive troponin I levels to exclude acute myocardial infarction from myocardial injury

  • Simona Ferraro EMAIL logo , Patrizia Boracchi , Matteo Santagostino , Giuseppe Marano , Chiara Vendramin , Lidia Rossi , Elia M. Biganzoli , Marcello Galvani , Aldo Clerico and Angelo S. Bongo
Published/Copyright: October 6, 2011

Abstract

Background: Third generation troponin assays should aid in the rule-out of acute myocardial infarction (AMI). The study aim was to assess the capability of admission measurement of ultra-sensitive troponin I (TnI-Ultra) to exclude AMI from other myocardial injury.

Methods: The first TnI-Ultra sample from 856 patients at presentation to the Emergency Department and subsequent admission to the Cardiac Care Unit were considered in this case series. Myoglobin was simultaneously detected in 684 patients.

Results: The sensitivity of the first single TnI-Ultra level was 82.5% in overall AMI, and similar in ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI), admitted, respectively at 3 and 8 h from symptoms. The diagnostic capability of a first single TnI-Ultra level was poor for both STEMI and NSTEMI to discriminate and rule-out overall AMI from myocardial injury, with an area under the receiver-operating curve of 0.65 and a negative likelihood ratio of 0.55. Adopting an optimal test threshold or adding myoglobin detection did not improve TnI-Ultra performances.

Conclusions: The capability of a first single TnI-Ultra level to exclude AMI from other myocardial injury in early and late presenters is poor. Addition of myoglobin assay offered no further improvement and was not considered useful.


Corresponding author: Dr. Simona Ferraro, Ospedale Maggiore della Carità, SCDO, Cardiologia 2, C.so Mazzini 18, 28100 Novara, Italy Phone: +39/3471598351, Fax: +39/03213733516

Received: 2011-3-9
Accepted: 2011-9-17
Published Online: 2011-10-06
Published in Print: 2012-01-01

©2011 by Walter de Gruyter Berlin Boston

Articles in the same Issue

  1. Editorial
  2. Targeted therapy for HER-2: personalized medicine for her, too
  3. Review
  4. Circulating levels of HER-2/neu oncoprotein in breast cancer
  5. Mini Review
  6. The human epidermal growth factor receptor 2 (HER2)
  7. Opinion Paper
  8. Proposed criteria for sorting examined properties in clinical laboratory reports
  9. Guidelines and Recommendations
  10. Properties and units in the clinical laboratory sciences, Part XXIII. The NPU terminology, principles and implementation –a user’s guide (Technical Report 2011) (IFCC–IUPAC)
  11. Genetics and Molecular Diagnostics
  12. Establishing high resolution melting analysis: method validation and evaluation for c-RET proto-oncogene mutation screening
  13. Decreased mRNA expression of CCL5 [RANTES] in Alzheimer's disease blood samples
  14. General Clinical Chemistry and Laboratory Medicine
  15. A risk-analysis approach to the evaluation of analytical quality
  16. C-statistics versus logistic regression for assessing the performance of qualitative diagnostic tests
  17. Detection and quantification of M-proteinemia: comparison of various methods for serum protein electrophoresis
  18. External quality assessment of point-of-care International Normalized Ratio (INR) testing in Europe
  19. Comparison of two point-of-care testing (POCT) devices for fetal lactate during labor
  20. Simultaneous quantification of 19 drugs/metabolites in urine important for pain management by liquid chromatography-tandem mass spectrometry
  21. Enzyme-linked immunoassay for plasma-free metanephrines in the biochemical diagnosis of phaeochromocytoma in adults is not ideal
  22. The old and new tests for celiac disease: which is the best test combination to diagnose celiac disease in pediatric patients?
  23. Improving diagnosis of adult-type hypolactasia in patients with abdominal complaints
  24. Synovial and serum levels of uncarboxylated matrix Gla-protein (ucMGP) in patients with arthritis
  25. The diagnostic performance of allergen-molecules in comparison to allergen-extracts
  26. Analytical performances of cystatin C turbidimetric assay: which impact on accuracy of glomerular filtration rate estimation in renal transplantation?
  27. Evaluation of Aution Max AX-4030 and 9UB Uriflet, 10PA Aution Sticks urine dipsticks in the automated urine test strip analysis
  28. Reference Values and Biological Variations
  29. Diurnal variability of total calcium during normal sleep and after an acute shift of sleep
  30. Infections Diseases
  31. Comparison of two immunoassays for determining hepatitis B virus serum markers
  32. Cardiovascular Diseases
  33. Ultra-sensitive troponin I levels to exclude acute myocardial infarction from myocardial injury
  34. Diabetes
  35. Extracellular matrix-associated (GAGs, CTGF), angiogenic (VEGF) and inflammatory factors (MCP-1, CD40, IFN-γ) in type 1 diabetes mellitus nephropathy
  36. Letters to the Editor
  37. Serum HER-2/ECD analysis in monitoring breast cancer patients
  38. No evidence for the involvement of the lipoxin A4 receptor (FPR2/ALX) gene in the susceptibility to coronary artery disease
  39. Does the presence of 3-epi-25OHD3 affect the routine measurement of vitamin D using liquid chromatography tandem mass spectrometry?
  40. Validity of the measurement of capillary cholesterol in the diagnosis of defined hypercholesterolemia
  41. Prelims
  42. Prelims
Downloaded on 10.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/cclm.2011.746/html
Scroll to top button